Prilosec Rx-to-OTC switch for heartburn to be sought by P&G and Astra Merck.
This article was originally published in The Tan Sheet
Executive Summary
PRILOSEC SWITCH TEAM P&G AND ASTRA MERCK will jointly contribute to the clinical work needed for approval of the Rx-to-OTC switch of the prescription ulcer drug omeprazole, and Procter & Gamble will handle the marketing of the OTC product once approved, the companies announced Dec. 15. Under the terms of the deal, P&G would make upfront payments to Astra Merck, plus royalties based on U.S. net sales of the OTC drug.
You may also be interested in...
AstraZeneca
U.S. Patent & Trademark Office publishes 10 Prilosec OTC trademarks, with varying suffixes: OTC, Fast Action, AC, AP, Heartburn Preventer, Gelcap, Acid Inhibitor, Heartburn Blocker, PM and HB. AstraZeneca has a joint development and marketing deal with Procter & Gamble for an OTC version of omeprazole for heartburn (1"The Tan Sheet" Dec. 22, 1997, p. 2). Net sales of the Rx proton pump inhibitor in 1998 totaled $3.1 bil. A recent Campbell Mithun Esty Health study cited $50 mil. in DTC ad spending on Prilosec, which has been the subject of a new ad campaign (2"The Tan Sheet" July 19, p. 8)
AstraZeneca
U.S. Patent & Trademark Office publishes 10 Prilosec OTC trademarks, with varying suffixes: OTC, Fast Action, AC, AP, Heartburn Preventer, Gelcap, Acid Inhibitor, Heartburn Blocker, PM and HB. AstraZeneca has a joint development and marketing deal with Procter & Gamble for an OTC version of omeprazole for heartburn (1"The Tan Sheet" Dec. 22, 1997, p. 2). Net sales of the Rx proton pump inhibitor in 1998 totaled $3.1 bil. A recent Campbell Mithun Esty Health study cited $50 mil. in DTC ad spending on Prilosec, which has been the subject of a new ad campaign (2"The Tan Sheet" July 19, p. 8)
AstraZeneca
U.S. Patent & Trademark Office publishes 10 Prilosec OTC trademarks, with varying suffixes: OTC, Fast Action, AC, AP, Heartburn Preventer, Gelcap, Acid Inhibitor, Heartburn Blocker, PM and HB. AstraZeneca has a joint development and marketing deal with Procter & Gamble for an OTC version of omeprazole for heartburn (1"The Tan Sheet" Dec. 22, 1997, p. 2). Net sales of the Rx proton pump inhibitor in 1998 totaled $3.1 bil. A recent Campbell Mithun Esty Health study cited $50 mil. in DTC ad spending on Prilosec, which has been the subject of a new ad campaign (2"The Tan Sheet" July 19, p. 8)